| Jiyun Shi, Ph.D, Associate Prof. Member of the Youth Innovation Promotion Association of CAS Institute of Biophysics, Chinese Academy of Sciences IBP-PKU Joint Lab of Molecular Imaging and Translational Medicine E-mail: shijiyun(AT)ibp.ac.cn Tel: (+86)(10)64888340; 15 Datun Road, Chaoyang District, Beijing, 100101, China |
Biography & Introduction
AREAS OF RESEARCH INTEREST
Molecular Imaging, Tumor Targeted Radiotherapy, Translational Nuclear Medicine.
EDUCATION
2008/9-2011/7 Ph.D. in Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing, China
2004/9-2007/7 Joint training Master student in Radiopharmaceuticals, China Institute of Atomic Energy and Peking University, China
2000/9-2004/7 Undergraduate Student in Chemistry, Chemistry College, Jilin University, Jilin Province, China
PROFESSIONAL EXPERIENCE
07/2014--Present:
Associate Professor, Interdisciplinary Laboratory, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
08/2011--07/2014:
Assistant Professor, Medical and Health Analytical Center & Medical Isotopes Research Center, Peking University, Beijing 100191, China
06/2010--01/2011:
Research Fellow, Molecular Imaging and Nanomedicine Laboratory, University of Toronto & University Health Network, Toronto, Canada
Mentor: Prof. Gang Zheng
10/2007--09/2008:
Visiting Scholar, Radiochemistry Laboratory, School of Health Sciences, Purdue University, Indiana, USA
Mentor: Prof. Shuang Liu
HONORS AND AWARDS
◆ 2011 Outstanding Graduate Award, Peking University
◆ 2011 The Promising Academic Research Talent Award, Peking University(HSC)
◆ 2011 Top Prize University Scholarship (top 5%)
◆ 2010 Scholarship Award for Excellent Doctoral Student granted by Ministry of Education (¥30,000/year)
◆ 2010 Academic Innovation Award, Peking University
◆ 2010 Merit Student Award, Peking University
◆ 2009 International Travel Award of 18th International Symposium on Radiopharmaceutical Sciences, International Atomic Energy Agency (IAEA)
◆ 2009 Academic Innovation Award, Peking University
◆ 2016 Gold Medal of the National Science and Technology Workers Innovation and Entrepreneurship Competition of the 18th China Association for Science and Technology Annual Conference
RESEARCH GRANTS
Source: National Natural Science Foundation (General Program)
Title: A Novel Molecular Probe for Imaging Diagnosis and Therapeutic Evaluation of HER2-Positive Tumors
Role: Principal Investigator
Period Covered: 01/2020 to 12/2023
Source: National Natural Science Foundation (General Program) Source: Beijing Natural Science Foundation (General Program)
Title: A Novel Molecular Probe for PET Imaging of Highly Metastatic Tumor Novel
Role: Principal Investigator
Period Covered: 01/2016 to 12/2019
Source: Beijing Natural Science Foundation (General Program)
Title: A Novel Molecular Probe Targeting Tumor Integrin αvβ3 Expression
Role: Principal Investigator
Period Covered: 01/2014 to 12/2016
Source: National Natural Science Foundation Youth Fund
Title: Porphyrin-Based Multifunctional Molecular Probe Targeting Tumor Integrin αvβ3 Expression
Role: Principal Investigator
Period Covered: 01/2012 to 12/2015
CLINICAL TRIAL APPROVAL
China Food and Drug Administration, a class 1 new drug clinical trial approval (drug name: 99mTc-3PRGD2 injection), approval number: 2018L02484. Currently in clinical phase III trials.
PATENTS
14 patents: ZL200810239036.X; ZL200910077039.2; ZL2014100840659; ZL201310304250.X; ZL201410084837.9; ZL201611095315.4; ZL2017103346344; ZL2017103341374; ZL201710713055.0; ZL201611095338.5; ZL201711113966.6; 201910378947.9; 2019107773304; 2019110099872.
SELECTED SCIENTIFIC PUBLICATIONS (# Co-first Author,* Corresponding Author)
1. Gao, H.; Luo, C.; Yang, G.; Du, S.; Li, X.; Zhao, H.; Shi, J.*; Wang, F*. Improved in Vivo Targeting Capability and Pharmacokinetics of (99m)Tc-Labeled isoDGR by Dimerization and Albumin-Binding for Glioma Imaging. Bioconjugate chemistry 2019, 30, 2038-2048.
2. Zhao H, Gao H, Zhai L, Liu X, Jia B, Shi J*, Wang F*. (99m)Tc-HisoDGR as a Potential SPECT Probe for Orthotopic Glioma Detection via Targeting of Integrin α5β1. Bioconjug Chem. 2016 May 18;27(5):1259-66.
3. Shi J, Wang F, Liu S. Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging. Biophys Rep. 2016;2(1):1-20. Review.
4. Jing L#, Shi J#, Fan D, Li Y, Liu R, Dai Z*, Wang F*, Tian J*. (177)Lu-Labeled Cerasomes Encapsulating Indocyanine Green for Cancer Theranostics. ACS Appl Mater Interfaces. 2015 Oct 7;7(39):22095-105.
5. Fan D, Zhang X, Zhong L, Liu X, Sun Y, Zhao H, Jia B, Liu Z, Zhu Z, Shi J*, Wang F*. (68)Ga-Labeled 3PRGD2 for Dual PET and Cerenkov Luminescence Imaging of Orthotopic Human Glioblastoma. Bioconjug Chem. 2015 Jun 17;26(6):1054-60.
6. Shi J, Fan D, Dong C, Liu H, Jia B, Zhao H, Jin X, Liu Z, Li F, Wang F. Anti-tumor effect of integrin targeted 177Lu-3PRGD2 and combined therapy with endostar. Theranostics. 2014, 4(3):256-66.
7. Shi J#, Jin Z#, Liu X, Fan D, Sun Y, Zhao H, Zhu Z, Liu Z, Jia B, Wang F. PET Imaging of Neovascularization with (68)Ga-3PRGD2 for Assessing Tumor Early Response to Endostar Antiangiogenic Therapy. Mol Pharm. 2014 Nov 3;11(11):3915-22.
8. Wu M#, Shi J#, Fan D, Zhou Q, Wang F, Niu Z, Huang Y. Biobehavior in normal and tumor-bearing mice of tobacco mosaic virus. Biomacromolecules. 2013 Nov 11;14(11):4032-7.
9. Luo H#, Shi J#, Jin H#, Fan D, Lu L, Wang F*, Zhang Z*. An (125)I-labeled octavalent peptide fluorescent nanoprobe for tumor-homing imaging in vivo. Biomaterials. 2012 Jun;33(19):4843-50.
10. Shi J, Zhou Y, Chakraborty S, Kim YS, Jia B, Wang F, Liu S. Evaluation of 111In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability. Theranostics. 2011;1:322-40.
11. Shi J#, Liu TW#, Chen J, Green D, Jaffray D, Wilson BC, Wang F, Zheng G. Transforming a Targeted Porphyrin Theranostic Agent into a PET Imaging Probe for Cancer. Theranostics. 2011;1:363-70.
12. Liu Z#, Shi J#, Jia B, Yu Z, Liu Y, Zhao H, Li F, Tian J, Chen X, Liu S, Wang F. Two (90)Y-Labeled Multimeric RGD Peptides RGD4 and 3PRGD2 for Integrin Targeted Radionuclide Therapy. Mol Pharm. 2011, 8(2):591-599.
13. Shi J, Wang L, Kim YS, Zhai S, Jia B, Wang F, Liu S. 99mTcO(MAG2-3G3-dimer): a new integrin αvβ3-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics. Eur J Nucl Med Mol Imaging. 2009, 36(11):1874-1884.
14. Shi J, Kim YS, Chakraborty S, Jia B, Wang F, Liu S. 2-Mercaptoacetylglycylglycyl (MAG2) as a Bifunctional Chelator for 99mTc-Labeling of Cyclic RGD Dimers: Effect of Technetium Chelate on Tumor Uptake and Pharmacokinetics. Bioconjug Chem. 2009, 20(8):1559-1568.
15. Shi J, Kim YS, Zhai S, Liu Z, Chen X, Liu S. Improving tumor uptake and pharmacokinetics of 64Cu-labeled cyclic RGD peptide dimers with Gly3 and PEG4 linkers. Bioconjug Chem. 2009, 20(4):750-759.
16. Shi J, Wang L, Kim YS, Zhai S, Liu Z, Chen X, Liu S.Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine -aspartic (RGD) dimers with triglycine linkers. J Med Chem. 2008, 51(24):7980-7990.
From:Jiyun Shi, 2019-11-01 update